First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

医学 皮疹 药效学 内科学 不利影响 药代动力学 肺癌 血液学 癌症 肿瘤科 实体瘤疗效评价标准 胃肠病学 临床研究阶段 化疗
作者
Yuanyuan Zhao,Yuxiang Ma,Aimin Zang,Ying Cheng,Yiping Zhang,Xiangcai Wang,Zhendong Chen,Song Qu,Jianbo He,Chuanben Chen,Chuan Jin,Dongyuan Zhu,Qingshan Li,Xianling Liu,Wuyun Su,Yi Ba,Yanrong Hao,Junmin Chen,Guoping Zhang,Shenhong Qu,Yong Li,Weineng Feng,Mengxiang Yang,Baorui Liu,Weiwei Ouyang,Liang Jin,Zhuang Yu,Xiaoyan Kang,Shilin Xue,Guihong Yang,Wei Yan,Yingying Yang,Zhi Liu,YuFeng Peng,Bill Fanslow,Xian Huang,Li Zhang,Hongyun Zhao
出处
期刊:Journal of Hematology & Oncology [Springer Nature]
卷期号:16 (1) 被引量:16
标识
DOI:10.1186/s13045-023-01445-1
摘要

Abstract Background QL1706 (PSB205) is a single bifunctional MabPair (a novel technical platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and anti-CTLA-4 IgG1), with a shorter elimination half-life (t 1/2 ) for CTLA-4. We report results from a phase I/Ib study of QL1706 in patients with advanced solid tumors who failed standard therapies. Methods In the phase I study, QL1706 was administered intravenously once every 3 weeks at one of five doses ranging from 0.3 to 10 mg/kg, and the maximum tolerated dose, recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of QL1706 were investigated. In the phase Ib study, QL1706 was administered at the RP2D intravenously every 3 weeks, and the preliminary efficacies in non-small cell lung cancer (NSCLC), nasopharyngeal carcinoma (NPC), cervical cancer (CC), and other solid tumors were evaluated. Results Between March 2020 and July 2021, 518 patients with advanced solid tumors were enrolled (phase I, n = 99; phase Ib, n = 419). For all patients, the three most common treatment-related adverse events (TRAEs) were rash (19.7%), hypothyroidism (13.5%), and pruritus (13.3%). The TRAEs and immune-related adverse events (irAEs) of grade ≥ 3 occurred in 16.0% and 8.1% of patients, respectively. In phase I, 2 of 6 patients in the 10mg/kg group experienced dose-limiting toxicities (DLTs) (grade 3 thrombocytopenia and grade 4 immune-mediated nephritis), so the maximum tolerated dose (MTD) was reached at 10 mg/kg. The RP2D was determined to be 5 mg/kg based on comprehensive analysis of tolerability, PK/PD, and efficacy. For all patients who received QL1706 at the RP2D, the objective response rate (ORR) and median duration of response were 16.9% (79/468) and 11.7 months (8.3—not reached [NR]), respectively; and the ORRs were 14.0% (17/121) in NSCLC, 24.5% (27/110) in NPC, 27.3% (15/55) in CC, 7.4% (2/27) in colorectal cancer, 23.1% (6/26) in small cell lung cancer. For immunotherapy-naive patients, QL1706 exhibited promising antitumor activities, especially in NSCLC, NPC, and CC, with ORRs of 24.2%, 38.7%, and 28.3%, respectively. Conclusions QL1706 was well tolerated and demonstrated promising antitumor activity in solid tumors, especially in NSCLC, NPC, and CC patients. It is currently being evaluated in randomized phase II (NCT05576272, NCT05179317) and phase III (NCT05446883, NCT05487391) trials. Trial Registration ClinicalTrials.gov Identifier: NCT04296994 and NCT05171790.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
琴power发布了新的文献求助10
1秒前
ZhiningZ完成签到 ,获得积分10
2秒前
123完成签到,获得积分10
2秒前
2秒前
yidi01完成签到,获得积分10
3秒前
共享精神应助LKSkywalker采纳,获得10
3秒前
调研昵称发布了新的文献求助50
4秒前
4秒前
5秒前
6秒前
大聪明完成签到,获得积分10
6秒前
lin发布了新的文献求助10
6秒前
跳跳发布了新的文献求助10
7秒前
我瞎蒙完成签到,获得积分10
8秒前
小蘑菇应助耍酷蛋挞采纳,获得10
9秒前
苗玉完成签到,获得积分10
9秒前
9秒前
minqiu发布了新的文献求助10
10秒前
加油干发布了新的文献求助30
10秒前
10秒前
10秒前
12发布了新的文献求助10
11秒前
齐天大圣完成签到,获得积分10
11秒前
11秒前
12秒前
12秒前
14秒前
鹿静枫发布了新的文献求助10
14秒前
雨齐完成签到,获得积分10
14秒前
开心榴莲大王完成签到 ,获得积分10
14秒前
武雨寒发布了新的文献求助10
14秒前
整齐的问凝完成签到,获得积分20
15秒前
从容芮应助llg采纳,获得10
16秒前
soar发布了新的文献求助10
16秒前
万松辉完成签到,获得积分20
17秒前
zengxi246发布了新的文献求助10
18秒前
18秒前
大气水池完成签到,获得积分10
18秒前
高分求助中
Sustainability in Tides Chemistry 2000
The ACS Guide to Scholarly Communication 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Pharmacogenomics: Applications to Patient Care, Third Edition 800
Ожившие листья и блуждающие цветы. Практическое руководство по содержанию богомолов [Alive leaves and wandering flowers. A practical guide for keeping praying mantises] 500
A Dissection Guide & Atlas to the Rabbit 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3079267
求助须知:如何正确求助?哪些是违规求助? 2731896
关于积分的说明 7521337
捐赠科研通 2380638
什么是DOI,文献DOI怎么找? 1262413
科研通“疑难数据库(出版商)”最低求助积分说明 611928
版权声明 597414